Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2016

Collaboration Agreement [Abstract]

Schedule of Related Party Transactions

The collaboration revenue the Company earned from Sanofi is detailed below:

	Year Ended December 31,
Sanofi Collaboration Revenue	2016			2015			2014
Antibody:
Reimbursement of Regeneron research and development expenses	$	564,900		$	735,439		$	547,761
Reimbursement of Regeneron commercialization-related expenses	322,149			157,350			19,480
Regeneron's share of losses in connection with commercialization of antibodies	(459,058		)	(240,042		)	(41,378		)
Other	12,177			10,243			10,243
Total Antibody	440,168			662,990			536,106
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	138,497			39,961			—
Other	80,000			40,000			—
Total Immuno-oncology	218,497			79,961			—
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	—			—			(4,715		)
Reimbursement of Regeneron research and development expenses	—			686			4,806
Other	—			15,236			5,102
Total ZALTRAP	—			15,922			5,193
	$	658,665		$	758,873		$	541,299

Schedule of Selected Financial Information - Sanofi

Other selected financial information in connection with the Company's collaboration agreements with Sanofi is as follows:

	As of December 31,
	2016		2015
Antibody:
Accounts receivable, net	$	47,268	$	126,687
Deferred revenue	98,741		84,237
Immuno-oncology:
Accounts receivable, net	$	40,647	$	21,394
Deferred revenue	520,000		600,000

Collaboration revenue

The collaboration revenue the Company earned from Bayer is detailed below:

	Year Ended December 31,
Bayer Collaboration Revenue	2016		2015		2014
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	649,232	$	466,667	$	301,302
Sales milestones	—		15,000		105,000
Cost-sharing of Regeneron EYLEA development expenses	9,010		8,887		23,383
Other	52,527		69,466		52,390
Total EYLEA	710,769		560,020		482,075
PDGFR-beta antibody:
Cost-sharing of rinucumab/aflibercept (REGN2176-3) development expenses	10,291		10,075		2,848
Other	9,576		10,393		10,632
Total PDGFR-beta antibody	19,867		20,468		13,480
Ang2 antibody:
Cost-sharing of nesvacumab/aflibercept (REGN910-3) development expenses	8,036		—		—
Other	5,598		—		—
Total Ang2 antibody	13,634		—		—
	$	744,270	$	580,488	$	495,555

Schedule of Selected Financial Information - Bayer

Deferred revenue in connection with the Company's collaboration agreements with Bayer is as follows:

	As of December 31,
	2016		2015
EYLEA	$	62,373	$	46,694
PDGFR-beta antibody	—		9,522
Ang2 antibody	45,739		—